InVivo shares plummet as first human trials of spinal cord treatment delayed
This article was originally published in Clinica
Executive Summary
InVivo Therapeutics’ stock took a bashing yesterday after the company revealed it was delaying a first-in-human trial of its biopolymer scaffold in acute spinal cord injury (SCI) until the first quarter of 2014. It had said in April that it planned to start the study, testing the safety and performance of the scaffold in five patients, “in the next few months,” after receiving investigational device exemption (IDE) approval from the US FDA.